Docket No.

259277US0

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Eugene ROUSSEL

SERIAL NO: 09/756,978 GAU: 1642

FILED: January 9, 2001 EXAMINER: CANELLA

FOR: THERAPEUTIC MODULATION OF THE TUMOR INFLAMMATORY RESPONSE

# INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

# REFERENCES

- ☑ The applicant(s) wish to make of record the Office Action received in the corresponding European Patent Application No. 02 720 778.6. A copy of the Action is attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### **RELATED CASES**

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

#### DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Daniel J. Pereira, Ph.D.

Registration No. 45,518

Frederick D. Vastine Registration No. 27,013

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Form PTO 1449		U.S. DEPARTMENT	OF COMMERCE	ATTY DOCKET NO.		SERIAL NO.		
(Modified) PATENT AND TRADEMARK OFFICE			259277US0	09/756,978				
		PE		APPLICANT				
LIST OF	REFE	RENCES CITED BY API	PUCANT	Eugene ROUSSEL			_	
n and se				FILING DATE		GROUP		
LIST OF REFERENCES CITED BY APPOCANT			January 9, 2001		1642			
		3.	NE T	U.S. PATENT DOCUMENTS				
EXAMINER		DOCUMENT TRAVE		NAME CLASS		SUB FILING DATE		
INITIAL		NUMBER	01/21/92	Palladino Michael	-	CLASS	IF A	PPROPRIATE
	AA	5,082,658	11/07/89	Chong Kong-Teck	-			
	AB	4,879,111	-		<del></del>			
	AC	5,446,033	08/29/95	Engel Juergen, et al.	ļ			<del></del>
	AD	5,474,981	12/12/95	Luster Andrew, et al.				
	AE	5,871,723	02/16/99	Polverini Peter, J. et al.			<u> </u>	····
	AF							
	AG						_	
	АН							
	Al							
	AJ							
	AK							
	AL							
	АМ							
	AN							
			FO	REIGN PATENT DOCUMENTS				
		DOCUMENT	DATE	COLINTRY		TRANSLATION		
		NUMBER	DATE	COUNTRY		YES N		NO
	AO	99/59599	11/25/99	WIPO				
	AP	00/01392	01/13/00	WIPO				
	AQ	01/62274	08/30/01	WIPO				
	AR		-		·			
	AS							
	AT	<b>3</b>			-	1818.11		
	AU							
	AV							-
		OTHER RE	EERENCES (	Including Author, Title, Date, Pertinent	Pages e	tc )		
				itumor Activity of Recombinant Interferor			tion with	Tumor Necrosis
	AW	Factors and Chemothe	rapeutic Agen	ts" International Journal of Immunopharm	nacology, \	∕ol. 7, No.	3, 1985,	, page 330
	AX							
	AY							
AZ					Addi	Additional References sheet(s) attached		
Examiner					Date Considered			
*Examiner: In conformance	itial if r	eference is considered, of considered. Include co	whether or not	citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw lii	ne through	citation	if not in